Back to all Programs

Past Event

Related Materials

Past Event

International Workshop on HBV Cure 2021

Viral Hepatitis and Liver Disease

HBV Cure 2021 - Message from OC Member

Viral Hepatitis and Liver Disease

Patient Selection for Clinical Trials Based on Drug Class - F. Zoulim, MD, PhD

Viral Hepatitis and Liver Disease

New Data From Combination Trials for Chronic Hepatitis B - Pietro Lampertico, MD, PhD

Viral Hepatitis and Liver Disease

New Combination Therapies in Hepatitis Delta Therapy - J. Glenn, MD, PhD

Viral Hepatitis and Liver Disease

What Can We Learn by Deploying Immunological Analysis in Phase II Clinical Trials? - A. Gehring, PhD

Viral Hepatitis and Liver Disease

TLR-8 Agonist - S. Fletcher, PhD

Viral Hepatitis and Liver Disease

Anti-HBs Antibody - C. Hwang, MD, PhD

Viral Hepatitis and Liver Disease

Immunotherapeutics in the Treatment of Chronic Hepatitis B - S. Browne, MD

Viral Hepatitis and Liver Disease

VBI-2601: Immunotherapeutic HBV Vaccine Candidate Overview - F. Diaz-Mitoma, MD, PhD

Viral Hepatitis and Liver Disease

HBV Immunotherapeutic Vaccines (Lessons from HCV) - E. Barnes, PhD, FRCP, F. Med. Sci.

Viral Hepatitis and Liver Disease

HBsAg Loss: A Predictor of Long-Term Clinical Outcomes - M. Peters, MD

Viral Hepatitis and Liver Disease

Outcomes After NUC Therapy Discontinuation - M. Cornberg, MD

Viral Hepatitis and Liver Disease

How to Handle Flares in HBV Trials With Novel Agents - H. Janssen, MD, PhD

Viral Hepatitis and Liver Disease

Safety Monitoring during HBV Clinical Trials and after Antiviral Discontinuation -P. Mishra, MD

Viral Hepatitis and Liver Disease

Biological Insights Taught by Clinical Responses to Novel Hbv/Hdv Drugs - S. Urban, PhD

Viral Hepatitis and Liver Disease

Core Inhibitors (Capsid Assembly Modulators) - L. Stamm, MD, PhD

Viral Hepatitis and Liver Disease

Antisense Oligos - L. Felton, BSc, PhD

Viral Hepatitis and Liver Disease

STOP Agents - M. McClure, MD

Viral Hepatitis and Liver Disease

Active Site Polymerase Inhibitor Nucleotides (APSINs) - D. Mayers, MD

Viral Hepatitis and Liver Disease

Update on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV - D. Manuilov, MD